CO5690570A2 - Nueva combinacion sinergistica que comprende roflumilast y formoterol - Google Patents
Nueva combinacion sinergistica que comprende roflumilast y formoterolInfo
- Publication number
- CO5690570A2 CO5690570A2 CO05062787A CO05062787A CO5690570A2 CO 5690570 A2 CO5690570 A2 CO 5690570A2 CO 05062787 A CO05062787 A CO 05062787A CO 05062787 A CO05062787 A CO 05062787A CO 5690570 A2 CO5690570 A2 CO 5690570A2
- Authority
- CO
- Colombia
- Prior art keywords
- formoterol
- roflumilast
- daily dose
- combined use
- combination including
- Prior art date
Links
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title abstract 7
- 229960002848 formoterol Drugs 0.000 title abstract 7
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title abstract 7
- 229960002586 roflumilast Drugs 0.000 title abstract 7
- 239000011885 synergistic combination Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 3
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- El uso combinado de roflumilast y formoterol paraprevenir los síntomas de trastornos del tracto respiratorio en humanos, o para tratarlos.2.- El uso combinado de roflumilast y formoterol paraprevenir los síntomas de trastornos del tracto respiratorio en humanos, o para tratarlos, caracterizado porque comprende administrar roflumilast en una dosis diaria de 100 a 500 µg, y formoterol en una dosis diaria de 10 a 120 µg.3.- Medicamento adecuado para el uso combinado de conformidad con la reivindicación 1 o 2, caracterizado porque comprende roflumilast y formoterol en una combinación fija o libre.4.- Medicamento de conformidad con la reivindicación 3, caracterizado además porque es una combinación oral fija.5.- Medicamento de conformidad con la reivindicación 3, caracterizado además porque es una combinación oral fija que contiene roflumilast en una dosis diaria de 100 a 500 µg y formoterol en una dosis diaria de 10 a 120 µg.6.- Medicamento de conformidad con la reivindicación 3, caracterizado además porque es una combinación libre que comprende roflumilast en una formulación oral y formoterol en una formulación adecuada para administración mediante inhalación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026505 | 2002-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5690570A2 true CO5690570A2 (es) | 2006-10-31 |
Family
ID=32338002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05062787A CO5690570A2 (es) | 2002-11-27 | 2005-06-27 | Nueva combinacion sinergistica que comprende roflumilast y formoterol |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20060142308A1 (es) |
| EP (1) | EP1567139B1 (es) |
| JP (1) | JP2006508994A (es) |
| KR (1) | KR101071798B1 (es) |
| CN (1) | CN100346777C (es) |
| AT (1) | ATE399543T1 (es) |
| AU (1) | AU2003292120B2 (es) |
| BR (1) | BR0316451A (es) |
| CA (1) | CA2506962C (es) |
| CO (1) | CO5690570A2 (es) |
| CY (1) | CY1110369T1 (es) |
| DE (1) | DE60321953D1 (es) |
| DK (1) | DK1567139T3 (es) |
| EA (1) | EA009935B1 (es) |
| ES (1) | ES2309357T3 (es) |
| HR (1) | HRP20050579B1 (es) |
| IL (1) | IL168308A (es) |
| IS (1) | IS2575B (es) |
| MA (1) | MA27539A1 (es) |
| ME (1) | ME00489B (es) |
| MX (1) | MXPA05005437A (es) |
| NO (1) | NO334247B1 (es) |
| NZ (1) | NZ540659A (es) |
| PL (1) | PL216752B1 (es) |
| PT (1) | PT1567139E (es) |
| RS (1) | RS51081B (es) |
| SI (1) | SI1567139T1 (es) |
| TN (1) | TNSN05131A1 (es) |
| UA (1) | UA83018C2 (es) |
| WO (1) | WO2004047829A1 (es) |
| ZA (1) | ZA200503308B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| BRPI0406427B8 (pt) | 2003-03-10 | 2021-05-25 | Astrazeneca Ab | processo para a preparação de roflumilast |
| WO2006097456A1 (en) * | 2005-03-16 | 2006-09-21 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
| DE102005030733A1 (de) * | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
| BRPI0713768A2 (pt) * | 2006-07-05 | 2012-10-30 | Nycomed Gmbh | combinação de inibidores de reductase de hmg-coa com inibidores de fosfodiesterase 4 para o tratamento de doenças pulmonares inflamatórias |
| WO2013077830A1 (en) * | 2011-11-25 | 2013-05-30 | Mahmut Bilgic | Synergistilly active combinations of roflumilast and carmoterol |
| US20130172303A1 (en) * | 2012-01-03 | 2013-07-04 | Forest Laboratories Holdings Ltd. | Roflumilast compositions for the treatment of copd |
| CA2897464C (en) * | 2013-01-28 | 2021-05-18 | Incozen Therapeutics Pvt. Ltd. | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
| CN104800214A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入气雾剂复方及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| SI0706513T1 (en) * | 1993-07-02 | 2002-10-31 | Altana Pharma Ag | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| HU227520B1 (hu) * | 1997-02-17 | 2011-07-28 | Nycomed Gmbh | ARDS és IRDS kezelésére szolgáló, 3-(ciklopropil-metoxi)-N-(3,5-diklór-4-piridinil)-4-(difluor-metoxi)-benzamidot és tüdõfelületaktív anyagot tartalmazó kompozíció |
| US6624181B1 (en) * | 1997-02-28 | 2003-09-23 | Altana Pharma Ag | Synergistic combination |
| DE59814173D1 (de) * | 1997-02-28 | 2008-04-03 | Nycomed Gmbh | Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten |
| US6288118B1 (en) * | 1998-08-26 | 2001-09-11 | Smithkline Beecham Corporation | Therapies for treating pulmonary diseases |
| US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
| EP1671651B1 (en) * | 1999-08-21 | 2009-11-11 | Nycomed GmbH | Synergistic combination of pumafentrine and salmeterol |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ES2296923T3 (es) * | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| US7291608B2 (en) * | 2001-04-30 | 2007-11-06 | Glaxo Group Limited | Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α |
-
2003
- 2003-11-26 CN CNB2003801037450A patent/CN100346777C/zh not_active Expired - Fee Related
- 2003-11-26 ES ES03767663T patent/ES2309357T3/es not_active Expired - Lifetime
- 2003-11-26 AT AT03767663T patent/ATE399543T1/de active
- 2003-11-26 MX MXPA05005437A patent/MXPA05005437A/es active IP Right Grant
- 2003-11-26 DE DE60321953T patent/DE60321953D1/de not_active Expired - Lifetime
- 2003-11-26 HR HRP20050579AA patent/HRP20050579B1/hr not_active IP Right Cessation
- 2003-11-26 NZ NZ540659A patent/NZ540659A/en not_active IP Right Cessation
- 2003-11-26 JP JP2004554480A patent/JP2006508994A/ja active Pending
- 2003-11-26 ME MEP-2008-782A patent/ME00489B/me unknown
- 2003-11-26 EP EP03767663A patent/EP1567139B1/en not_active Expired - Lifetime
- 2003-11-26 BR BR0316451-9A patent/BR0316451A/pt not_active IP Right Cessation
- 2003-11-26 CA CA2506962A patent/CA2506962C/en not_active Expired - Fee Related
- 2003-11-26 UA UAA200505966A patent/UA83018C2/uk unknown
- 2003-11-26 PL PL377732A patent/PL216752B1/pl unknown
- 2003-11-26 EA EA200500774A patent/EA009935B1/ru not_active IP Right Cessation
- 2003-11-26 RS YUP-2005/0382A patent/RS51081B/sr unknown
- 2003-11-26 US US10/535,816 patent/US20060142308A1/en not_active Abandoned
- 2003-11-26 SI SI200331344T patent/SI1567139T1/sl unknown
- 2003-11-26 DK DK03767663T patent/DK1567139T3/da active
- 2003-11-26 WO PCT/EP2003/013275 patent/WO2004047829A1/en not_active Ceased
- 2003-11-26 AU AU2003292120A patent/AU2003292120B2/en not_active Ceased
- 2003-11-26 PT PT03767663T patent/PT1567139E/pt unknown
- 2003-11-26 KR KR1020057009210A patent/KR101071798B1/ko not_active Expired - Fee Related
-
2005
- 2005-04-25 ZA ZA200503308A patent/ZA200503308B/en unknown
- 2005-05-01 IL IL168308A patent/IL168308A/en not_active IP Right Cessation
- 2005-05-10 TN TNP2005000131A patent/TNSN05131A1/en unknown
- 2005-06-16 MA MA28343A patent/MA27539A1/fr unknown
- 2005-06-17 NO NO20052999A patent/NO334247B1/no not_active IP Right Cessation
- 2005-06-20 IS IS7898A patent/IS2575B/is unknown
- 2005-06-27 CO CO05062787A patent/CO5690570A2/es not_active Application Discontinuation
-
2008
- 2008-09-17 CY CY20081101017T patent/CY1110369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23468B7 (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
| ES2202265T3 (es) | Aerosol medicamentoso en el tratamiento o la prevencion del dolor. | |
| BR0108730A (pt) | Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados | |
| ES2162927T3 (es) | Formulacion para la aplicacion por inhalacion. | |
| AR065579A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| AR101593A2 (es) | Formulación superfina de formoterol | |
| RU2010105122A (ru) | Композиции для ухода за полостью рта, продукты и способы применения | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| CO5611092A2 (es) | Formulacion superfina de formoterol | |
| CO6150188A2 (es) | Uso de teencteplasa para tratar un ictus isquemico agudo | |
| CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
| AR065580A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| BR112017026417B1 (pt) | Formulação para o tratamento de distúrbios da boca, garganta e vias respiratórias | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| CO5690570A2 (es) | Nueva combinacion sinergistica que comprende roflumilast y formoterol | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| CO5540290A2 (es) | Composicion que comprende un inhibidor de pde-4 y antagonista del receptor-hi y su uso en la manufactura de un medicamento para el tratamiento de enfermedades respiratorias | |
| GB2430623A (en) | Medicaments for treating chronic respiratory disease | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
| Elwood et al. | Midazolam coinduction does not delay discharge after very brief propofol anaesthesia | |
| JPH09500610A (ja) | 経鼻芳香放出組成物 | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| Ko et al. | Effects of topical O24 essential oils on patients with fibromyalgia syndrome: a randomized, placebo controlled pilot study | |
| MX384760B (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. | |
| UY26595A1 (es) | Formulaciones de entecavir de dosis bajas y uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |